COMMUNIQUÉS West-GlobeNewswire

Orion Corporation: Managers' transactions - Jari Karlson

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Jari Karlson Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]

Orion Corporation: Managers' transactions - Christer Nordstedt

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Christer Nordstedt Orion Corporation has received the following disclosure under Market Abuse [...]

Orion Corporation: Managers' transactions - Liisa Hurme

02/03/2018 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 2 nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]

Oasmia Pharmaceutical AB (publ)

02/03/2018 - 08:30

Interim report for the period May 2017 – January 2018 Commercial focus and lower cost base THIRD QUARTER November 1, 2017 – January 31, 2018 Consolidated net sales amounted to TSEK 656 compared to TSEK 36 in the third [...]

Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2017

02/03/2018 - 08:01

Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2017 Clinical development progressed as planned Highlights in January-December 2017: Phase 1 clinical study of Herantis Pharma ("Herantis") [...]

Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients

02/03/2018 - 08:00

LONDON, March 02, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA ) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]

NeuroSearch A/S – Annual General Meeting 2018

02/03/2018 - 08:00

Announcement no. 3-18 Page 1 of 1 Announcement 2 March 2018 NeuroSearch A/S (NEUR) will conduct the company's Annual General Meeting on Monday, 30 April 2018. Shareholders who wish to submit motions for the Annual [...]

ESPERITE (ESP) : L1 Capital subscribes to the 16th tranche of investment today

02/03/2018 - 07:18

Amsterdam, The Netherlands - 2 March 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 16 th Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]

Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma

02/03/2018 - 07:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) FDA to review Dupixent ® (dupilumab) as potential treatment for moderate-to-severe asthma Paris and Tarrytown, NY - March 2, 2018 - The U.S. Food and Drug [...]

Sanofi : La FDA va examiner Dupixent® (dupilumab) comme traitement potentiel de l'asthme modéré à sévère

02/03/2018 - 07:01

Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) La FDA va examiner Dupixent ® (dupilumab) comme traitement potentiel de l'asthme modéré à sévère Paris et Tarrytown (New York) - 2 mars 2018 - La Food and [...]

ABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTION

02/03/2018 - 07:01

GHENT, Belgium, 2 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that the first patient has been dosed in the Japanese Phase II study of ALX-0171, the Company's wholly-owned inhaled Nanobody® [...]

Tyme Technologies Announces Pricing of its Offering of 9 Million Shares of Common Stock

02/03/2018 - 03:46

NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME ) (the “Company”) announced today that it has priced its underwritten public offering of 9 million shares of its common stock, par value [...]

Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies

01/03/2018 - 23:14

IRVING, Texas, March 01, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA ) (Reata or Company), a clinical-stage biopharmaceutical company, today announced top-line data from the dose-escalation [...]

Dentsply Sirona Reports Preliminary Fourth Quarter and Full Year 2017 Results

01/03/2018 - 23:01

Reported Q4 revenues of $1,091.0 million, up 9.5% compared to prior year; constant currency growth 1 of 5.3% A Q4 2017 GAAP EPS loss of $2.95 including incremental non-cash charges of $847.9 million Q4 2017 non-GAAP [...]

3D Signatures Reports Quarter Ended December 31, 2017 Financial Results

01/03/2018 - 23:00

TORONTO, March 01, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS" ), a personalized medicine company with a proprietary software platform based on the three- [...]

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018

01/03/2018 - 22:52

CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE ), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers [...]

Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

01/03/2018 - 22:45

BERKELEY, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX ) today announced that on March 1, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant [...]

MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018

01/03/2018 - 22:30

SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK ), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable [...]

Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results

01/03/2018 - 22:30

BOSTON, March 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq: ZFGN ), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]